CALCIUM-ANTAGONISTS AS 1ST-LINE ANTIHYPERTENSIVE AGENTS - A PLACEBO-CONTROLLED, COMPARATIVE TRIAL OF ISRADIPINE AND NIFEDIPINE

被引：0
|
作者：
WELZEL, D [1 ]
BURGER, KJ [1 ]
WEIDINGER, G [1 ]
机构：
[1] SANDOZ AG,DEPT CLIN RES,NURNBERG,GERMANY
来源：
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | 1990年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S70 / S74
页数：5
相关论文
共 50 条
  • [31] Biomarker (BM) results from MERiDiAN, a double-blind placebo (PLA)-controlled randomized phase 3 trial of 1st-line paclitaxel (PAC) with or without bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)
    Das Thakur, M.
    Bais, C.
    Estay, I.
    Vaidyanathan, R.
    O'Shaughnessy, J.
    Cameron, D.
    Hubeaux, S.
    Quah, C.
    Miles, D.
    CANCER RESEARCH, 2016, 76
  • [32] LOW-DOSE CALCITRIOL PREVENTS THE RISE IN 1,84 IPTH WITHOUT AFFECTING SERUM-CALCIUM AND PHOSPHATE - PROSPECTIVE PLACEBO-CONTROLLED MULTICENTER TRIAL
    RITZ, E
    KUSTER, S
    SCHMIDTGAUK, H
    STEIN, G
    SCHOLZ, C
    KRAATZ, G
    HEIDLAND, A
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 887 - 887
  • [33] AngLT-1: Protocol and Launch of a Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of Angiotensin II as a Second-Line Vasopressor in Liver Transplantation
    Bokoch, Michael
    Adelmann, Dieter
    Kothari, Rishi
    Marcus, Sivan
    Tran, Amy
    Sun, Elizabeth
    Reddy, Meghana
    Pardo, Manuel
    Legrand, Matthieu
    ANESTHESIA AND ANALGESIA, 2023, 136 : 445 - 446
  • [34] A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy.: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial.
    Shepherd, FA
    Pereira, J
    Ciuleanu, TE
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Bezjak, A
    Tu, D
    Santabárbara, P
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 622S - 622S
  • [35] Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes
    Herbst, Roy S.
    Stern, Howard
    Amler, Lukas
    Otterson, Gregory
    Lin, Ming
    O'Connor, Paula
    Hainsworth, John
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S323 - S323
  • [36] Biomarker evaluation in the Phase Ill, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes
    Herbst, Roy
    Stern, Howard
    Amler, Lukas
    Otterson, Gregory
    Lin, Ming
    O'Connor, Paula
    Hainsworth, John
    CANCER RESEARCH, 2009, 69
  • [37] Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction
    Traverse, Jay H.
    McKenna, David H.
    Harvey, Karen
    Jorgenso, Beth C.
    Olson, Rachel E.
    Bostrom, Nancy
    Kadidlo, Diane
    Lesser, John R.
    Jagadeesan, Vikrant
    Garberich, Ross
    Henry, Timothy D.
    AMERICAN HEART JOURNAL, 2010, 160 (03) : 428 - 434
  • [38] A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Interferon β-1a Formulations for S.C. Administration in Patients with Remitting Multiple Sclerosis: First-Year Results
    Boiko A.N.
    Bosenko L.P.
    Vasilovskii V.V.
    Volkova L.I.
    Zakharova M.N.
    Kotov S.V.
    Lekomtseva E.V.
    Negrich T.I.
    Parshina E.V.
    Patrusheva O.P.
    Prokopenko S.V.
    Sazonov D.V.
    Timchenko P.V.
    Trinitatskii Y.V.
    Khabirov F.A.
    Khavunka M.Y.
    Chichanovskaya L.V.
    Sherman M.A.
    Lin’kova Y.N.
    Zinkina-Orikhan A.V.
    Tursunova K.B.
    Neuroscience and Behavioral Physiology, 2018, 48 (7) : 883 - 889
  • [39] Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)
    Ritz, E
    Kuster, S
    SchmidtGayk, H
    Stein, G
    Scholz, C
    Kraatz, G
    Heidland, A
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 (12) : 2228 - 2234
  • [40] Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
    Zeidan, Amer M.
    Ando, Kiyoshi
    Rauzy, Odile
    Turgut, Mehmet
    Wang, Ming -Chung
    Cairoli, Roberto
    Hou, Hsin-An
    Kwong, Yok-Lam
    Arnan, Montserrat
    Meers, Stef
    Pullarkat, Vinod
    Santini, Valeria
    Malek, Kamel
    Kiertsman, Flavia
    Niolat, Julie
    Ramos, Pedro Marques
    Menssen, Hans D.
    Fenaux, Pierre
    Miyazaki, Yasushi
    Platzbecker, Uwe
    LANCET HAEMATOLOGY, 2024, 11 (01): : e38 - e50
12345